Matching-Adjusted Indirect Comparison of Tarlatamab for Patients with Platinum-Refractory or Platinum-Resistant Extensive-Stage Small-Cell Lung Cancer.
Franziska Dirnberger, Sachin Patel, Devon J Boyne et al.
✦ AI-curated · Sources linked
In 30 seconds
This study conducted a matching-adjusted indirect comparison of tarlatamab versus paclitaxel and CAV in patients with platinum-refractory or platinum-resistant extensive-stage small-cell lung cancer (ES-SCLC). The analysis revealed that tarlatamab was associated with longer overall survival compared to paclitaxel (HR 0.35) and CAV (HR 0.48), suggesting a potential benefit in this patient population.
Key findings
- Tarlatamab showed longer overall survival compared to paclitaxel (HR 0.35, p < 0.001).
- Tarlatamab also demonstrated longer overall survival compared to CAV (HR 0.48, p < 0.001).
- Tarlatamab improved progression-free survival, overall response rate, and disease control rate relative to paclitaxel (p < 0.05).
- No significant differences were found between tarlatamab and CAV regarding PFS, ORR, or DCR (p > 0.05).
Why it matters
The findings indicate that tarlatamab may offer improved survival outcomes for patients with limited treatment options due to platinum-refractory or platinum-resistant ES-SCLC, highlighting the need for effective second-line therapies in this aggressive cancer.
What to keep in mind
These findings are subject to residual confounding and should be interpreted with caution.